---
title: >-
  Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of
  Obeticholic Acid in TARGET-PBC.
description: >-
  Explore this publication on real-world evidence: Primary Biliary Cholangitis
  (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in
  TARGET-PBC..
date: '2018-01-01'
category: Publications
tags:
  - Approval / Commercialization
  - Care
  - DDW
  - PBC
  - Health System Partner
  - Pharma Partner
  - Poster Presentation
  - Hepatology
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/approval-commercialization/primary-biliary-cholangitis-pbc-in-the-u-s-real-world/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: primary-biliary-cholangitis-pbc-in-the-u-s-real-world
id: wGnnzEFOnjQmw2yA8sxdd
contentType: article
---

## Challenge

OCA was approved for PBC in 2016 but its real-world effectiveness and safety profile in the more advanced, heterogeneous US patient population—which includes higher proportions of cirrhosis and AIH overlap than registration trial populations—had not been established.

## Solution

The TARGET-PBC cohort was used to characterize OCA treatment patterns, biochemical response rates, and adverse events—including pruritus-related discontinuation—in 63 OCA-treated patients, comparing real-world effectiveness to the POISE registration trial in a more advanced population.

## Impact

Demonstrating that OCA achieves comparable biochemical responses in a more advanced real-world population to those seen in registration trials supports the external validity of clinical trial results and provides real-world effectiveness context for prescriber and payer communications.